Mounjaro diarrhoea and burping: causes, patterns and when to act

What the trial data actually showed about gut symptoms

The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed more than 2,500 adults with obesity over 72 weeks. Gastrointestinal side effects (nausea, diarrhoea, vomiting, constipation and burping) were the most frequently reported adverse events across all tirzepatide doses. Diarrhoea occurred in a meaningful proportion of participants, with rates broadly in line with other GLP-1 and dual-agonist medicines. Burping (eructation) was also documented, though it tends to attract less attention in trial write-ups than nausea does.

The NHS tirzepatide medicines page confirms the same picture: loose stools, diarrhoea, burping and indigestion sit in the common-to-very-common bracket for this medicine. That does not mean every person experiences them (many people tolerate Mounjaro well from the first pen) but it does mean they are expected, not alarming in themselves.

The underlying mechanism matters here. Tirzepatide acts on both GIP and GLP-1 receptors, slowing gastric emptying significantly. Food sitting longer in the upper gut produces more gas, more reflux and, for some people, looser stools as the bowel adapts to altered transit. You can read a clear summary of how this works on the Mounjaro overview page, and a closer look at the burping side specifically is covered in our guide to Mounjaro side effects and burping.

Why diarrhoea and burping often cluster together on Mounjaro

Patients often notice that diarrhoea and burping arrive together rather than separately, and there is a physiological reason for that. Slowed gastric emptying means food ferments longer in the stomach and small intestine. This produces gas (hence the burping) while the altered motility pattern simultaneously unsettles the lower gut, producing looser, more urgent stools. The effect can be more pronounced after fatty meals, large portions or eating quickly, because the stomach is already working more slowly than usual.

Eggy or sulphurous burping, a variant some patients find particularly unpleasant, is covered in detail at our page on eggy burps and diarrhoea on Mounjaro. The practical short version: smaller, lower-fat meals, eating slowly and avoiding carbonated drinks reduce both symptoms for most people. Keeping a rough food diary in the early weeks can help you spot personal triggers. Our guide to Mounjaro wind and burping has a fuller list of dietary adjustments worth trying.

These symptoms typically peak within the first week of a new dose and settle as the body acclimatises, a pattern the NICE appraisal of tirzepatide (TA1026) acknowledged in its tolerability discussion. If they have not eased after two to three weeks at a stable dose, that is worth raising with your prescriber rather than waiting longer.

When to get medical help, the symptoms that cannot wait

Most diarrhoea on Mounjaro is self-limiting and manageable. A few presentations, though, need prompt attention.

Contact a doctor or NHS 111 the same day if diarrhoea is severe enough to cause significant fluid loss and you cannot keep fluids down, dehydration can develop quickly and puts the kidneys under strain. Signs to watch: little or no urine output, dizziness when standing, dry mouth and rapid heartbeat.

Seek emergency medical assessment if you develop severe, persistent abdominal pain that spreads towards your back, with or without vomiting. This can be a sign of acute pancreatitis. In January 2026 the MHRA issued a Drug Safety Update specifically highlighting pancreatitis as a known but infrequent serious risk with GLP-1 medicines, and advising patients and clinicians to take this symptom pattern seriously. The relevant safety information is on the MHRA Drug Safety Update index.

If you suspect your symptoms are related to the medicine, you or your prescriber can report them via the MHRA Yellow Card scheme, patient reports directly influence how regulators monitor these medicines over time. Worth doing.

Practical help for managing diarrhoea specifically, including whether medicines like loperamide are appropriate, is covered in our guide to Mounjaro diarrhoea and Imodium.

How a prescriber approach differs from self-managing alone

Pushing through persistent diarrhoea or burping without telling anyone means your prescriber cannot help. Dose timing, the pace of titration and dietary guidance are all adjustable, but only if the prescriber knows there is a problem. The NHS tirzepatide page is direct on this point: tell your doctor or pharmacist if side effects bother you or do not go away.

At nume, our clinical team (led by prescribers including our clinical director) reviews every patient before a repeat order is dispatched. That is the checkpoint where symptom patterns get addressed, not overlooked. If you are already on treatment and struggling, our aftercare team is available seven days a week. If you are considering Mounjaro and want to understand how side effects are monitored from the start, the consultation is the right place to raise that. Your pen arrives by tracked DPD delivery the next working day in plain, unbranded packaging, but the clinical oversight that supports what's inside it starts well before that.

For a broader picture of the full side-effect profile, the Mounjaro side effects overview covers the complete range, and our dedicated diarrhoea guide goes deeper on that symptom alone. Our prescribers discuss suitability and side-effect management as a standard part of the consultation, start yours at our treatment page.